Abstract
The article covers the results of clinical application of a domestic drug based on recombinant tumor necrosis factor-alphathymosin-alpha1 (Refnot) in 20 patients with metastatic skin melanoma. Refnot was administered at a dose of 100 000 IU subcutaneously 1–5 days every week, the cycle 3 or 4 weeks. During the therapy the levels of vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) were determined in patients serum before therapy, every 3 or 4 weeks of treatment until disease progression. In patients with stabilization of the disease showed a decreasing level of VEGF and FGF. In the case of the detection of the progression level of VEGF and FGF have.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
